Nordic Capital completed the acquisition of a majority stake in Evosep.

Nordic Capital, a private equity investor, completed the acquisition of a majority stake in Evosep, an innovator of sample preparation and separation solutions for LC-MS-based proteomics. Financial terms were not disclosed. "Nordic Capital has great expertise across biopharma, medtech and diagnostics, and we are thrilled to have them onboard as Evosep is moving into the next growth phase. Together, we aim to redefine how proteomics drives efficiency, quality, and insight across healthcare and life sciences. Evosep's mission remains set in stone, and customers can expect us to continue pushing forward the standardization of LCMS-based proteomics with impactful products and solutions," Morten Bern, Evosep CEO.